russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2023-5334russjcardiol-5334Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWПроблема перекрестного риска прогрессирования артериальной гипертензии, синдрома обструктивного апноэ сна и COVID-19The problem of cross risk of arterial hypertension progression, obstructive sleep apnea syndrome and COVID-19https://orcid.org/0000-0001-5517-4591ПоповК. А.PopovК. A.

Попов Константин Андреевич — аспирант кафедры факультетской терапии лечебного факультета.

Саратов

Saratov

Kostyanze@yandex.ruhttps://orcid.org/0000-0002-9104-8020БулаеваЮ. В.BulaevaYu. V.

Булаева Юлия Викторовна — кандидат медицинских наук, ассистент кафедры факультетской терапии лечебного факультета.

Саратов

Saratov

19vita@mail.ruhttps://orcid.org/0000-0003-3778-1288ЕрмасоваС. А.ErmasovaS. A.

Ермасова Светлана Александровна — кандидат медицинских наук, ассистент кафедры факультетской терапии лечебного факультета.

Саратов

Saratov

sver4@yandex.ruhttps://orcid.org/0000-0002-5205-7311ШварцЮ. Г.ShvartsYu. G.

Шварц Юрий Григорьевич — доктор медицинских наук, профессор, заведующий кафедрой факультетской терапии лечебного факультета.

Саратов

Saratov

shwartz58@yandex.ruФГБОУ ВО Саратовский государственный медицинский университет имени В.И. Разумовского Минздрава РоссииРоссияV.I. Razumovsky Saratov State Medical UniversityRussian Federation202321052023282SОбразование53345334Copyright © Попов К.А., Булаева Ю.В., Ермасова С.А., Шварц Ю.Г., 20232023Попов К.А., Булаева Ю.В., Ермасова С.А., Шварц Ю.Г.Popov К.A., Bulaeva Y.V., Ermasova S.A., Shvarts Y.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/5334

Обзор рассматривает факторы риска прогрессирования артериальной гипертензии (АГ), синдрома обструктивного апноэ сна (СОАС) и новой коронави- русной инфекции (COVID-19) как потенциальные переменные для прогностических моделей оценки вероятности дестабилизации упомянутых состояний. Большинство опубликованных исследований рассматривает АГ и СОАС как факторы риска, влияющие на течение COVID-19, в то время как нетяжелая COVID-19 угрожает в отношении дестабилизации АГ и СОАС. Кроме того, COVID-19, АГ и СОАС взаимосвязаны с качеством сна. Снижение качества сна часто может быть как следствием, так и отягощающим течение этих заболеваний фактором, а также обуславливать повышенную уязвимость для острых заболеваний. Повышенный индекс массы тела — универсальный фактор риска для многих заболеваний и клинических состояний, а контроль массы тела повышает степень контроля заболеваний, ассоциированных с ожирением. Кроме того, снижение качества сна часто может быть как следствием любого из состояний, упомянутых выше, так и отягощающим течение этих заболеваний фактором. Также перспективным направлением для совершенствования прогностических моделей является анализ вегетативной дисфункции у пациентов.

This review considers the risk factors for arterial hypertension (AH) progression, obstructive sleep apnea syndrome (OSAS) and novel coronavirus infection (COVID-19) as potential variables for the prognostic models of estimating the probability of destabilization of the mentioned conditions. The most published studies consider AH and OSAS as the risk factors influencing the course of COVID-19, while moderate and mild COVID-19 can be destabilizing factor regarding to AH and OSAS. In addition, COVID-19, AH and OSAS are interrelated with sleep quality. The worsening of sleep quality often can be both a consequence of these diseases and a factor aggravating their course, and also can cause the increased vulnerability to acute diseases. An increased body mass index is a universal risk factor for many diseases and clinical conditions, and the monitoring of body mass increases the degree of the control of the diseases associated with obesity. In addition, the worsening of sleep quality can be both a consequence of any of above-mentioned conditions and a factor aggravating their course. Also, a promising direction for improving prognostic models is the analysis of autonomic dysfunction in patients.

COVID-19артериальная гипертензиясиндром обструктивного апноэ снаоценка прогнозаCOVID-19arterial hypertensionobstructive apnea sleep syndromeprognosis estimationReferencesGold MS, Sehayek D, Gabrielli S, et al. COVID-19 and comorbidities: a systematic review and meta-analysis. Postgrad Med. 2020:132:8,749-55. doi:10.1080/00325481.2020.1786964.Gold MS, Sehayek D, Gabrielli S, et al. COVID-19 and comorbidities: a systematic review and meta-analysis. Postgrad Med. 2020:132:8,749-55. doi:10.1080/00325481.2020.1786964.Тарловская Е. И., Арутюнов А. Г., Конради А.О. и др. Анализ влияния препаратов базовой терапии, применявшихся для лечения сопутствующих заболеваний в период, предшествующий инфицированию, на риск летального исхода при новой коронавирусной инфекции. Данные международного регистра "Анализ динамики Коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2" (АКТИВ SARS-CoV-2). Кардиология. 2021;61(9):20-32. doi:10.18087/cardio.2021.9.n1680.Tarlovskaya EI, Arutyunov AG, Konradi AO, et al. Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry ("Analysis of chronic non-infectious diseases dynamics after COVID-19 infection in adult patients SARS- CoV-2"). Kardiologiia. 2021;61(9):20-32. (In Russ.) doi:10.18087/cardio.2021.9.n1680.Senaratna CV, Perret JL, Lodge CJ, et al. Prevalence of obstructive sleep apnea in the general population: A systematic review. Sleep Med Rev. 2017;34:70-81. doi:10.1016/J.SMRV.2016.07.002.Senaratna CV, Perret JL, Lodge CJ, et al. Prevalence of obstructive sleep apnea in the general population: A systematic review. Sleep Med Rev. 2017;34:70-81. doi:10.1016/J.SMRV.2016.07.002.Shah NA, Yaggi HK, Concato J, Mohsenin V. Obstructive sleep apnea as a risk factor for coronary events or cardiovascular death. Sleep and Breathing. 2010;14(2):131-6. doi:10.1007/s11325-009-0298-7.Shah NA, Yaggi HK, Concato J, Mohsenin V. Obstructive sleep apnea as a risk factor for coronary events or cardiovascular death. Sleep and Breathing. 2010;14(2):131-6. doi:10.1007/s11325-009-0298-7.Welty FK, Rajai N, Amangurbanova M. Comprehensive Review of Cardiovascular Complications of Coronavirus Disease 2019 and Beneficial Treatments. Cardiol Rev. 2022;30(3):145-57. doi:10.1097/CRD.0000000000000422.Welty FK, Rajai N, Amangurbanova M. Comprehensive Review of Cardiovascular Complications of Coronavirus Disease 2019 and Beneficial Treatments. Cardiol Rev. 2022;30(3):145-57. doi:10.1097/CRD.0000000000000422.Pinto JA, Ribeiro DK, da Silva Cavallini AF, et al. Comorbidities associated with obstructive sleep apnea: A retrospective study. Int Arch Otorhinolaryngol. 2016;20(2):145-50. doi:10.1055/s-0036-1579546.Pinto JA, Ribeiro DK, da Silva Cavallini AF, et al. Comorbidities associated with obstructive sleep apnea: A retrospective study. Int Arch Otorhinolaryngol. 2016;20(2):145-50. doi:10.1055/s-0036-1579546.Miller MA, Cappuccio FP. A systematic review of COVID-19 and obstructive sleep apnoea. Sleep Med Rev. 2021;55:101382. doi:10.1016/j.smrv.2020.101382.Miller MA, Cappuccio FP. A systematic review of COVID-19 and obstructive sleep apnoea. Sleep Med Rev. 2021;55:101382. doi:10.1016/j.smrv.2020.101382.Лышова О.В., Костенко И.И. Предикторы синдрома обструктивного апноэ сна по данным клинического исследования и результатам суточного мониторирования артериального давления. Кардиология. 2018;58(9):12-20. doi:10.18087/cardio.2018.9.10169.Lyshova OV, Kostenko II. Predictors of obstructive sleep apnea syndrome according to results of clinical examintion and ambulatory blood pressure monitoring. Kardiologiya. 2018;58(9):12-20. (In Russ.) doi:10.18087/cardio.2018.9.10169.Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation. 2021;144(3):E56-E67. doi:10.1161/CIR.0000000000000988.Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation. 2021;144(3):E56-E67. doi:10.1161/CIR.0000000000000988.Kovacs DK, Gede N, Szabo L, et al. Weight reduction added to CPAP decreases blood pressure and triglyceride level in OSA: Systematic review and meta-analysis. Clin Transl Sci. 2022;15(5):1238-48. doi:10.1111/cts.13241.Kovacs DK, Gede N, Szabo L, et al. Weight reduction added to CPAP decreases blood pressure and triglyceride level in OSA: Systematic review and meta-analysis. Clin Transl Sci. 2022;15(5):1238-48. doi:10.1111/cts.13241.Venkataraman S, Vungarala S, Covassin N, Somers VK. Sleep apnea, hypertension and the sympathetic nervous system in the adult population. J Clin Med. 2020;9(2):591. doi:10.3390/jcm9020591.Venkataraman S, Vungarala S, Covassin N, Somers VK. Sleep apnea, hypertension and the sympathetic nervous system in the adult population. J Clin Med. 2020;9(2):591. doi:10.3390/jcm9020591.Ziegler MG, Milic M, Elayan H. Cardiovascular regulation in obstructive sleep apnea. Drug Discov Today Dis Models. 2011;8(4):155-60. doi:10.1016/J.DDMOD.2011.03.003.Ziegler MG, Milic M, Elayan H. Cardiovascular regulation in obstructive sleep apnea. Drug Discov Today Dis Models. 2011;8(4):155-60. doi:10.1016/J.DDMOD.2011.03.003.Popov K, Novitskiy A, Shvarts NA. Blood Pressure Level and Laboratory Indicators of Disease Severity in Patients with Arte-Rial Hypertension and COVID-19. European Journal of Preventive Cardiology. 2021;28,Supplement 1:zwab061.166. doi:10.1093/eurjpc/zwab061.166.Popov K, Novitskiy A, Shvarts NA. Blood Pressure Level and Laboratory Indicators of Disease Severity in Patients with Arte-Rial Hypertension and COVID-19. European Journal of Preventive Cardiology. 2021;28,Supplement 1:zwab061.166. doi:10.1093/eurjpc/zwab061.166.Lo K, Woo B, Wong M, Tam W. Subjective sleep quality, blood pressure, and hypertension: a meta-analysis. J Clin Hypertens. 2018;20(3):592-605. doi:10.1111/jch.13220.Lo K, Woo B, Wong M, Tam W. Subjective sleep quality, blood pressure, and hypertension: a meta-analysis. J Clin Hypertens. 2018;20(3):592-605. doi:10.1111/jch.13220.Deng J, Zhou F, Hou W, et al. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann N Y Acad Sci. 2021;1486(1):90-111. doi:10.1111/nyas.14506.Deng J, Zhou F, Hou W, et al. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann N Y Acad Sci. 2021;1486(1):90-111. doi:10.1111/nyas.14506.Strohle A. Physical activity, exercise, depression and anxiety disorders. J Neural Transm. 2009;116(6):777-84. doi:10.1007/s00702-008-0092-x.Strohle A. Physical activity, exercise, depression and anxiety disorders. J Neural Transm. 2009;116(6):777-84. doi:10.1007/s00702-008-0092-x.Mousavi SA, Heydari K, Mehravaran H, et al. Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial. J Med Virol. 2022;94(1):263-71. doi:10.1002/jmv.27312.Mousavi SA, Heydari K, Mehravaran H, et al. Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial. J Med Virol. 2022;94(1):263-71. doi:10.1002/jmv.27312.Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697-707. doi:10.1038/s41586-022-04569-5.Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697-707. doi:10.1038/s41586-022-04569-5.Montalvan V, Lee J, Bueso T, et al. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. Clin Neurol Neurosurg. 2020;194:105921. doi:10.1016/j.clineuro.2020.105921.Montalvan V, Lee J, Bueso T, et al. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. Clin Neurol Neurosurg. 2020;194:105921. doi:10.1016/j.clineuro.2020.105921.Wang L, Sievert D, Clark AE, et al. A human three-dimensional neural-perivascular ‘assembloid' promotes astrocytic development and enables modeling of SARS-CoV-2 neuropathology. Nat Med. 2021;27:1600-6. doi:10.1038/s41591-021-01443-1.Wang L, Sievert D, Clark AE, et al. A human three-dimensional neural-perivascular ‘assembloid' promotes astrocytic development and enables modeling of SARS-CoV-2 neuropathology. Nat Med. 2021;27:1600-6. doi:10.1038/s41591-021-01443-1.Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500-15. doi:10.1007/s00125-020-05180-x.Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500-15. doi:10.1007/s00125-020-05180-x.Dafallah Albashir AA. The potential impacts of obesity on COVID-19. Clinical Medicine, Journal of the Royal College of Physicians of London. 2020;20(4):E109-E113. doi:10.7861/CLINMED.2020-0239.Dafallah Albashir AA. The potential impacts of obesity on COVID-19. Clinical Medicine, Journal of the Royal College of Physicians of London. 2020;20(4):E109-E113. doi:10.7861/CLINMED.2020-0239.Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;16(7):341-2. doi:10.1038/s41574-020-0364-6.Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;16(7):341-2. doi:10.1038/s41574-020-0364-6.Scherer PE, Kirwan JP, Rosen CJ. Post-acute sequelae of COVID-19: A metabolic perspective. Elife. 2022;11:e78200. doi:10.7554/eLife.78200.Scherer PE, Kirwan JP, Rosen CJ. Post-acute sequelae of COVID-19: A metabolic perspective. Elife. 2022;11:e78200. doi:10.7554/eLife.78200.lo Presti E, Nuzzo D, al Mahmeed W, et al. Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health. Biochim Biophys Acta Mol Basis Dis. 2022;1868(12). doi:10.1016/j.bbadis.2022.166559.lo Presti E, Nuzzo D, al Mahmeed W, et al. Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health. Biochim Biophys Acta Mol Basis Dis. 2022;1868(12). doi:10.1016/j.bbadis.2022.166559.Master H, Annis J, Huang S, et al. Association of step counts over time with the risk of chronic disease in the All of Us Research Program. Nat Med. 2022;28:2301-8. doi:10.1038/s41591-022-02012-w.Master H, Annis J, Huang S, et al. Association of step counts over time with the risk of chronic disease in the All of Us Research Program. Nat Med. 2022;28:2301-8. doi:10.1038/s41591-022-02012-w.Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015-21. doi:10.1001/jama.284.23.3015.Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015-21. doi:10.1001/jama.284.23.3015.Pasha S, Kumar S, Chatterjee AB, Krishnaswamy G. An obstructive sleep apnea primer: What the practicing allergist needs to know. Annals of Allergy, Asthma and Immunology. 2017;118(3):259-68. doi:10.1016/j.anai.2016.07.033.Pasha S, Kumar S, Chatterjee AB, Krishnaswamy G. An obstructive sleep apnea primer: What the practicing allergist needs to know. Annals of Allergy, Asthma and Immunology. 2017;118(3):259-68. doi:10.1016/j.anai.2016.07.033.Rahman A, Tabassum T, Araf Y, et al. Silent hypoxia in COVID-19: pathomechanism and possible management strategy. Mol Biol Rep. 2021;48(4):3863-9. doi:10.1007/s11033-021-06358-1.Rahman A, Tabassum T, Araf Y, et al. Silent hypoxia in COVID-19: pathomechanism and possible management strategy. Mol Biol Rep. 2021;48(4):3863-9. doi:10.1007/s11033-021-06358-1.Bickler PE, Feiner JR, Lipnick MS, McKleroy W. "Silent" Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19. Anesthesiology. 2021;134(2):262-9. doi:10.1097/ALN.0000000000003578.Bickler PE, Feiner JR, Lipnick MS, McKleroy W. "Silent" Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19. Anesthesiology. 2021;134(2):262-9. doi:10.1097/ALN.0000000000003578.Bikov A, Meszaros M, Schwarz EI. Coagulation and Fibrinolysis in Obstructive Sleep Apnoea. Int J Mol Sci. 2021;22(6):2834. doi:10.3390/ijms22062834.Bikov A, Meszaros M, Schwarz EI. Coagulation and Fibrinolysis in Obstructive Sleep Apnoea. Int J Mol Sci. 2021;22(6):2834. doi:10.3390/ijms22062834.Perkins GD, Ji C, Connolly BA, et al. Effect of Noninvasive Respiratory Strategies on Intubation or Mortality among Patients with Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial. JAMA — Journal of the American Medical Association. 2022;327(6):546-58. doi:10.1001/jama.2022.0028.Perkins GD, Ji C, Connolly BA, et al. Effect of Noninvasive Respiratory Strategies on Intubation or Mortality among Patients with Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial. JAMA — Journal of the American Medical Association. 2022;327(6):546-58. doi:10.1001/jama.2022.0028.Hu M, Han X, Ren J, et al. Significant association of obstructive sleep apnoea with increased risk for fatal COVID-19: A quantitative meta-analysis based on adjusted effect estimates. Sleep Med Rev. 2022;63:101624. doi:10.1016/j.smrv.2022.101624.Hu M, Han X, Ren J, et al. Significant association of obstructive sleep apnoea with increased risk for fatal COVID-19: A quantitative meta-analysis based on adjusted effect estimates. Sleep Med Rev. 2022;63:101624. doi:10.1016/j.smrv.2022.101624.Kenney MJ, Ganta CK. Autonomic nervous system and immune system interactions. Compr Physiol. 2014;4(3):1177-200. doi:10.1002/cphy.c130051.Kenney MJ, Ganta CK. Autonomic nervous system and immune system interactions. Compr Physiol. 2014;4(3):1177-200. doi:10.1002/cphy.c130051.Moulson N, Petek BJ, Drezner JA, et al. SARS-CoV-2 Cardiac Involvement in Young Competitive Athletes. Circulation. 2021;144(4):256-66. doi:10.1161/CIRCULATIONAHA.121.054824.Moulson N, Petek BJ, Drezner JA, et al. SARS-CoV-2 Cardiac Involvement in Young Competitive Athletes. Circulation. 2021;144(4):256-66. doi:10.1161/CIRCULATIONAHA.121.054824.del Rio R, Marcus NJ, Inestrosa NC. Potential Role of Autonomic Dysfunction in Covid-19 Morbidity and Mortality. Front Physiol. 2020;11:561749. doi:10.3389/fphys.2020.561749.del Rio R, Marcus NJ, Inestrosa NC. Potential Role of Autonomic Dysfunction in Covid-19 Morbidity and Mortality. Front Physiol. 2020;11:561749. doi:10.3389/fphys.2020.561749.Bonaz B. Parameters matter: modulating cytokines using nerve stimulation. Bioelectron Med. 2020;6(1):12. doi:10.1186/s42234-020-00049-1.Bonaz B. Parameters matter: modulating cytokines using nerve stimulation. Bioelectron Med. 2020;6(1):12. doi:10.1186/s42234-020-00049-1.Labarca G, Gower J, Lamperti L, et al. Chronic intermittent hypoxia in obstructive sleep apnea: a narrative review from pathophysiological pathways to a precision clinical approach. Sleep and Breathing. 2020;24(2):751-60. doi:10.1007/s11325-019-01967-4.Labarca G, Gower J, Lamperti L, et al. Chronic intermittent hypoxia in obstructive sleep apnea: a narrative review from pathophysiological pathways to a precision clinical approach. Sleep and Breathing. 2020;24(2):751-60. doi:10.1007/s11325-019-01967-4.Mehra R, Chung MK, Olshansky B, et al. Sleep-Disordered Breathing and Cardiac Arrhythmias in Adults: Mechanistic Insights and Clinical Implications: A Scientific Statement From the American Heart Association. Circulation. 2022;146(9):E119-E136. doi:10.1161/CIR.0000000000001082.Mehra R, Chung MK, Olshansky B, et al. Sleep-Disordered Breathing and Cardiac Arrhythmias in Adults: Mechanistic Insights and Clinical Implications: A Scientific Statement From the American Heart Association. Circulation. 2022;146(9):E119-E136. doi:10.1161/CIR.0000000000001082.Pan Y, Yu Z, Yuan Y, et al. Alteration of Autonomic Nervous System Is Associated With Severity and Outcomes in Patients With COVID-19. Front Physiol. 2021;12:630038. doi:10.3389/fphys.2021.630038.Pan Y, Yu Z, Yuan Y, et al. Alteration of Autonomic Nervous System Is Associated With Severity and Outcomes in Patients With COVID-19. Front Physiol. 2021;12:630038. doi:10.3389/fphys.2021.630038.Skazkina VV, Popov KA, Krasikova NS. Spectral analysis of signals of autonomic regulation of blood circulation in patients with COVID-19 and arterial hypertension. Cardio-IT. 2021;8(2):e0201. doi:10.15275/cardioit.2021.0201.Skazkina VV, Popov KA, Krasikova NS. Spectral analysis of signals of autonomic regulation of blood circulation in patients with COVID-19 and arterial hypertension. Cardio-IT. 2021;8(2):e0201. doi:10.15275/cardioit.2021.0201.South AM, Diz DI, Chappell C. COVID-19, ACE2, and the cardiovascular consequences. PERSPECTIVES Integrative Cardiovascular Physiology and Pathophysiology. Am J Physiol Heart Circ Physiol. 2020;318:1084-90. doi:10.1152/ajpheart.00217.2020.South AM, Diz DI, Chappell C. COVID-19, ACE2, and the cardiovascular consequences. PERSPECTIVES Integrative Cardiovascular Physiology and Pathophysiology. Am J Physiol Heart Circ Physiol. 2020;318:1084-90. doi:10.1152/ajpheart.00217.2020.Iannelli A, Favre G, Frey S, et al. Obesity and COVID-19: ACE 2, the Missing Tile. Obes Surg. 2020;30(11):4615-7. doi:10.1007/s11695-020-04734-7.Iannelli A, Favre G, Frey S, et al. Obesity and COVID-19: ACE 2, the Missing Tile. Obes Surg. 2020;30(11):4615-7. doi:10.1007/s11695-020-04734-7.Bandyopadhyay D, Akhtar T, Hajra A, et al. COVID-19 Pandemic: Cardiovascular Complications and Future Implications. American Journal of Cardiovascular Drugs. 2020;20(4):311-24. doi:10.1007/s40256-020-00420-2.Bandyopadhyay D, Akhtar T, Hajra A, et al. COVID-19 Pandemic: Cardiovascular Complications and Future Implications. American Journal of Cardiovascular Drugs. 2020;20(4):311-24. doi:10.1007/s40256-020-00420-2.Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (Covid-19) and cardiovascular disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc. 2020;9(7):e016219. doi:10.1161/JAHA.120.016219.Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (Covid-19) and cardiovascular disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc. 2020;9(7):e016219. doi:10.1161/JAHA.120.016219.Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID- 19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hypertension. 2020;75(6):1382-5. doi:10.1161/HYPERTENSIONAHA.120.15082.Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID- 19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hypertension. 2020;75(6):1382-5. doi:10.1161/HYPERTENSIONAHA.120.15082.Flacco ME, Acuti Martellucci C, Bravi F, et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart. 2020;106(19):1519-24. doi:10.1136/heartjnl-2020-317336.Flacco ME, Acuti Martellucci C, Bravi F, et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart. 2020;106(19):1519-24. doi:10.1136/heartjnl-2020-317336.Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-15. doi:10.1038/s41591-021-01283-z.Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-15. doi:10.1038/s41591-021-01283-z.

The authors declare that there are no conflicts of interest present.